JERUSALEM, April 9, 2017 /PRNewswire/ -- Intec Pharma Ltd.
(Nasdaq: NTEC), a clinical stage biopharmaceutical company focused
on developing drugs based on its proprietary Accordion Pill™
platform technology, today announced the appointment of
Jeffrey A. Meckler as Vice Chairman
of its Board of Directors, effective immediately.
"We are delighted to welcome Jeff to the Intec Board," commented
John W. Kozarich, Ph.D., Chairman of
the Board of Intech Pharma. "Jeff's rich industry experience and
insights into corporate development strategies are renowned in the
industry. Our innovative drug delivery platform technology will
benefit greatly from Jeff's efforts. In addition, his joining the
Intec Pharma team dovetails with our goal to extend the U.S. and
global footprint of Intec and enhance the broader recognition of
our technology."
Mr. Meckler brings to Intec Pharma more than 25 years of life
sciences executive experience. Mr. Meckler spent more than 17 years
at Pfizer, where he held leadership positions in corporate
strategic planning, acquisitions and business development, market
research, manufacturing systems and sales operations analysis. Most
recently, Mr. Meckler was Chief Executive Officer of Cocrystal
Pharma, Inc. Previously, Mr. Meckler was a director of QLT Inc.,
and initially the principal executive officer during its
transformation into an orphan drug company. He has served on
numerous corporate boards and is currently a director of Retrophin,
Inc.
"I am eager to be joining the Intec Pharma team," said
Jeffrey Meckler. "It will be
exciting to help maximize the potential of the Accordion Pill
technology and its various therapeutic programs, such as the
Parkinson's disease program. I look forward to working with my
fellow directors and the management team to help grow Intec
Pharma."
Mr. Meckler earned his J.D. from Fordham
University School of Law and is admitted to the New York
Bar. He earned an M.S. in Industrial Administration and a B.S. in
Industrial Management from Carnegie Mellon University.
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes four product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients;
Accordion Pill Zaleplon, or AP-ZP, which is being developed for the
treatment of insomnia, including sleep induction and the
improvement of sleep maintenance; an Accordion Pill that is being
developed for the prevention and treatment of gastroduodenal and
small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID)-induced
ulcers; and AP-CBD/THC, an Accordion Pill with the two primary
cannabinoids contained in Cannabis sativa, cannabidiol (CBD)
and tetrahydrocannabinol (THC), which is being developed for
various indications including low back neuropathic pain and
fibromyalgia.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company's control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company's filings with the Securities and Exchange Commission,
and include the following: the company's ability to develop and
commercialize its product candidates and obtain additional
financing necessary therefor; the length, cost and uncertain
results of the company's clinical trials; including uncertainty
regarding the Company's ability to enroll the required number of
patients therein; the potential of adverse side effects, other
safety risks, or legal prohibitions on the use of certain products
in certain jurisdictions that could preclude the approval of the
company's drug candidates; the availability of reimbursement from
government authorities and health insurance companies for the
company's products; the impact of product liability lawsuits; and
the influence of extensive and costly government regulation.
Contacts
Zeev Weiss
Chief Executive Officer
Intec Pharma
+972-(2)586-4657
zeev@intecpharma.com
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intec-pharma-appoints-us-life-sciences-executive-jeffrey-a-meckler-to-its-board-of-directors-as-vice-chairman-300436956.html
SOURCE Intec Pharma Ltd.